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Complex regional pain syndrome 1--the Swiss cohort study
Abstract
BACKGROUND: Little is known about the course of Complex Regional Pain Syndrome 1 and potential
factors influencing the course of this disorder over time. The goal of this study is a) to set up a database
with patients suffering from suspected CRPS 1 in an initial stadium, b) to perform investigations on
epidemiology, diagnosis, prognosis, and socioeconomics within the database and c) to develop a
prognostic risk assessment tool for patients with CRPS 1 taking into account symptomatology and
specific therapies. METHODS/DESIGN: Prospective cohort study. Patients suffering from a painful
swelling of the hand or foot which appeared within 8 weeks after a trauma or a surgery and which
cannot be explained by conditions that would otherwise account for the degree of pain and dysfunction
will be included. In accordance with the recommendations of International Classification of
Functioning, Disability and Health (ICF model), standardised and validated questionnaires will be used.
Patients will be monitored over a period of 2 years at 6 scheduled visits (0 and 6 weeks, 3, 6, 12, and 24
months). Each visit involves a physical examination, registration of therapeutic interventions, and
completion of the various study questionnaires. Outcomes involve changes in health status, quality of
life and costs/utility. DISCUSSION: This paper describes the rationale and design of patients with
CRPS 1. Ideally, potential risk factors may be identified at an early stage in order to initiate an early and
adequate treatment in patients with increased risk for delayed recovery.
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Abstract
Background: Little is known about the course of Complex Regional Pain Syndrome 1 and
potential factors influencing the course of this disorder over time. The goal of this study is a) to set
up a database with patients suffering from suspected CRPS 1 in an initial stadium, b) to perform
investigations on epidemiology, diagnosis, prognosis, and socioeconomics within the database and
c) to develop a prognostic risk assessment tool for patients with CRPS 1 taking into account
symptomatology and specific therapies.
Methods/design: Prospective cohort study. Patients suffering from a painful swelling of the hand
or foot which appeared within 8 weeks after a trauma or a surgery and which cannot be explained
by conditions that would otherwise account for the degree of pain and dysfunction will be included.
In accordance with the recommendations of International Classification of Functioning, Disability
and Health (ICF model), standardised and validated questionnaires will be used. Patients will be
monitored over a period of 2 years at 6 scheduled visits (0 and 6 weeks, 3, 6, 12, and 24 months).
Each visit involves a physical examination, registration of therapeutic interventions, and completion
of the various study questionnaires. Outcomes involve changes in health status, quality of life and
costs/utility.
Discussion: This paper describes the rationale and design of patients with CRPS 1. Ideally,
potential risk factors may be identified at an early stage in order to initiate an early and adequate
treatment in patients with increased risk for delayed recovery.
Trial registration: Not applicable
Background
Complex Regional Pain Syndrome (CRPS) is a painful
condition with clinical features that include pain, sensory-
, sudomotor and vasomotor disturbances, trophic
changes and impaired motor function [1]. Symptoms usu-
ally appear after an initiating noxious event such as
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self-limiting to chronic disease with a high impact on
daily functioning and quality of life [4]. CRPS is often
associated with a significant morbidity and loss of quality
of life [5]. Just recently, Duman et al. reported that in Tur-
key almost a third of patients with CRPS are not returning
to work [6]. In a retrospective chart review of 143 patients
with CRPS who had been assessed and/or treated at a uni-
versity-based pain centre in the United States, over half of
all patients were involved in worker compensation claims
[7] and a fifth of all patients in law suits [7].
Information regarding relevant prognostic factors in CRPS
is sparse or difficult to interpret, due to the specificity of
circumstances in which the information was collected [8].
For the initiation of CRPS 1 certain psychological charac-
teristics such as depression, recent life events or emotional
instability are considered to be prognostic factors [9]. The
nature and severity of the initiating event does not seem
to have a prognostic value on the course of the disease
[10]. In the literature, the following parameters have been
identified as prognostic factors for delayed recovery: dura-
tion of the complaints (more than 90 days), cold CRPS 1,
passive coping style and poor controllability of the com-
plaints [11,12].
The goal of this study is a) to set up a database with
patients suffering from suspected CRPS 1 in an initial
stage, b) to perform investigations on epidemiology, diag-
nosis, prognosis, and socioeconomics within the database
and c) to develop a prognostic risk assessment tool for
patients with CRPS 1 taking into account symptomatol-
ogy and specific therapies. Ideally, risk factors are recog-
nized that are present early in the disease course so that
patients with increased risk for delayed recovery can be
identified early and treated adequately to minimize per-
sistent pain and functional disability.
Methods/Design
Study design
The prospective cohort study follows an observational
study design with a consecutive registration of patients
with CRPS 1 for two years. Thereafter, we intend to extend
the follow up of this cohort pending on further funding.
Study population
We will include all consenting eligible patients suffering
from a painful swelling of the hand or foot which
appeared within 8 weeks after a trauma or a surgery and
which cannot be explained by conditions that would oth-
erwise account for the degree of pain and dysfunction.
Inclusion criteria
1. Painful swelling of the hand or foot which appeared
within 8 weeks after a trauma or a surgery and which can-
not be explained by conditions that would otherwise
account for the degree of pain and dysfunction.
2. One single extremity is affected.
3. Sings and symptoms are still present at first visit.
4. Patients able to attend follow-up visits at Balgrist Uni-
versity Hospital, Zurich, Switzerland.
5. Age limit 18 years or older.
6. Signed informed consent.
Rationale for inclusion criteria
Our inclusion criteria are set very broadly. This allows us
to distinguish between those subjects with CRPS like
manifestations and others fulfilling diagnostic criteria of
current classification systems. This approach has several
advantages. First we are able to develop statistical tools to
identify manifestational profiles that are unlikely to
develop CRPS. Moreover we are able to study differences
in the prognosis of patients with CRPS like symptoms
from patients fulfilling the CRPS criteria. Finally, our over
inclusive enrolment has the potential to inform new clas-
sification systems for CRPS with a focus on prognosis
rather than diagnosis.
Exclusion criteria
1. Other conditions which appeared before the initiating
event or which can explain signs and symptoms better
than CRPS 1.
2. Signs and symptoms on more than one extremity.
3. Gravidity, lactation.
National and international collaboration
After an initial period, we plan collaboration with other
Swiss national medical centres and societies from medical
specialists, insurance companies and patient societies.
Internationally, we collaborate with the Trauma Related
Neuronal dysfunction (TREND) research consortium
from the Netherlands [13].
Procedure
We will recruit participants through direct referral from
primary care physicians and medical specialists in physi-
cal medicine & rehabilitation, rheumatologists, neurolo-
gists, pain specialists and orthopaedic surgeons. FB, UW
and RK perform the screening visit with possible partici-
pants. Subjects who meet the eligibility criteria will receive
further information concerning the study. In particular,
the aims and methods will be explained after which writ-
ten consent to participate will be sought. This trial hasPage 2 of 7
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University Hospital (Spezialisierte Unterkomission fur
Orthopadie der Kantonalen Ethikkommission, Zurich,
Switzerland, reference number EK01/2008).
Assessments will be performed after 6 weeks, 3 months, 6
months, 12 months, 18 months and 24 months. The
study follows a strictly observational design in which the
therapeutic intervention will be registered and classified
according to the list below (see table 1) and treatment
effects will be recorded for several health related out-
comes. The focus will be on observing the course of the
disorder over time and to identify significant risk factors
that may change the course in a positive or negative way.
Patients undergo individual treatment protocols based on
best current internationally accepted guidelines [14-16].
In order to exclude other underlying causes that may
account for the degree of pain or limitation exhibited by
the patient, additional laboratory tests or imaging meth-
ods will be performed at the discretion of the physician.
However, a minimal set of diagnostic tests will be
obtained in every participants (C-reactive protein and
conventional x-ray of both hands respectively feet). To
determine the positive diagnosis of CRPS 1 we will use the
IASP criteria [17]. Simultaneously, we will collect a broad
set of CRPS associated signs and symptoms. This addi-
tional information will help us to classify the patients
according to other diagnostic criteria sets (e.g. [10,18,19])
and allows us to perform future adaptations due to chang-
ing concepts in CRPS taxonomy.
Safety monitoring and adverse events
Since this study follows an observational design without
an actual intervention there is no substantial risk associ-
ated with participation. There is no additional physical
and physiological discomfort to be expected with partici-
pation. However, any unexpected events and adverse
events will be registered and followed. The investigator
will take care that all subjects are kept informed. All
adverse events will be followed until they have abated, or
until a stable situation has been reached. Depending on
the event, follow up may require additional tests or med-
ical procedures as indicated, and/or referral to the primary
care physician or a medical specialist.
Outcome measures (baseline & follow up)
Figure 1 outlines the way how we will evaluate the health
status of the participants. The assessments were chosen in
order to cover the domains as described in the ICF model
[20]. The consequences of CRPS 1 will be monitored at
different levels such as body structure and function, activ-
ity and participation as well as contextual factors influenc-
ing a person's health condition. Table 2 summarizes the
instrument used per evaluation point.
Socioeconomic Analysis
Cost analysis
Both direct health care costs, direct non-healthcare costs
(patient cost) and indirect cost (productivity losses) will
be included in the analysis. Direct health care costs
include the costs of the diagnostic and prognostic trajec-
tory and staff time (primary care physicians, specialists in
physical medicine & rehabilitation, rheumatology, neu-
rology, pain specialists and orthopaedic surgeons.). Vol-
umes will be collected using existing registration systems
and cost diaries. Non-medical costs such as productivity
losses, time and travel costs and other out-of-pocket costs
for undergoing diagnostic procedures or treatment will be
registered using cost diaries. This diary will be handed
over to patients upon their first visit. Cost calculation will
be based on real prices or on unit prices from the Swiss
Guideline for Cost Calculation. In case of household
activities, or other unpaid activities foregone, shadow
prices will be used.
Table 1: Categories of treatment
Pharmacological treatment:
Topical medications: Topical anaesthetics, topical capsaicin
Oral medications: Acetaminophen, NSAR, opioids, antidepressants, anticonvulsive medications
Other medications: Corticosteroids, calcitonin, bisphosphonates, vitamin c, nifedipin
Interventional therapies:
Sympathetic blockades, intravenous regional anaesthetic blocks, intravenous blocks, other blocks, neurolytic sympathetic blocks
Implanted therapies:
Peripheral nerve stimulation, spinal cord stimulator
Functional restoration:
Physical therapy, occupational therapy
Behavioural therapy:
Cognitive therapy, behavioural therapyPage 3 of 7
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Since this is a consecutive registration of eligible patients,
a sample size calculation is not necessary. After enrolling
the first 100 patients, we perform an internal quality
assessment and, if necessary, perform procedural changes.
When the value of a combination of several variables
needs to be quantified no straight forward methods to
estimate the required sample size are available. A fre-
quently used "rule of thumb" recommends that for each
variable included in the analysis, at least 10 patients with
a positive outcome (in this case the resolution of symp-
toms or other outcomes) are necessary [21]. Based on the
assumption that about one third of patients will not
return to work (indicating chronification) and the assess-
ment of about 30 covariates we will need to enrol about
700 patients.
Statistical analysis
Epidemiologic data and patient characteristics available
on continuous scales will be presented with medians and
interquartile ranges or means and standard deviations as
appropriate. Categorical data will be presented as rates
and percentages.
Associations between individual (independent) variables
and the outcome variables will be reported using correla-
tion coefficients. Results from univariate analysis will
inform multivariate modeling.
Assessment of causal associations will be performed using
multivariate models including potential confounders
along with the independent variables of interest. Prognos-
tic scores will be built using either multivariate logistic
Integrated research model based on ICF model (adapted from [8])Figu e 1
Integrated research model based on ICF model (adapted from[8]).
Structure & Function 
Visual Analogue Scale 
McGill Pain Questionnaire 
Semmes-Wein-stein Monofilament test 
Thermometry 
Range of motion 
Bradikinesia measurement 
Fahn-Marsden Dystonia Scale 
TREND Symptoms Inventory 
Case Report Forms Upper & Lower Limb
Activity Participation 
Radboud Skills Questionnaire 
Walking Ability Questionnaire 
Rising & Sitting Ability Questionnaire
Social Involvement Questionnaire
Health Condition
Demographic & disease related variables, 
Medication
Global Health 
SF-36 
EQ-5D
Enviromental Factors Personal Factors 
Co-Morbidity 
Age, sex, size, weight, BMI 
Alcohol, smoking 
Tampa Scale of Kinesiophobia 
Hospital Anxiety & Depression scale 
Living situation 
Education
EmploymentPage 4 of 7
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Models will be validated in cross samples. Calibration and
discrimination of the Cross validated prognostic instru-
ments will be assessed using the Brier Score. Missing data
will be imputed using multiple imputation methods if the
assumption that missingness is at random seems justifia-
ble.
Discussion
This paper describes the rationale and design of a prospec-
tive cohort study following the course of CRPS 1. We
intend to set-up a prospectively acquired clinical database
for two years. To our knowledge this is the first attempt to
set up a prospective cohort study with CRPS 1 patients.
We believe that the project is timely. From a socioeco-
nomic and epidemiological perspective many questions
regarding CRPS remain unanswered. While considerable
efforts have gone into basic science research dealing with
pathogenesis of CRPS the clinical counterpart has not
been vigorously fostered. Among the few examples we are
aware of the Dutch consortium Trend which established a
registry of cases with CRPS I. We think that our collabora-
tion with this group has a significant synergistic capacity.
Our partnership will contribute to a better understanding
of many important aspects of CRPS and inform the future
research agenda in this area. It is likely to generate consid-
erable transfer value to the health care system not only
because its results will have a direct impact on patient care
but also because it allows identifying patients requiring
Table 2: Outcome measures (adapted from [8])
Assessments and Instruments Baseline 6 weeks 3 months 6 months 12 months 24 months
Baseline Variables
Demographic variables x x x x x x
Disease related variables x
Medication x x x x x x
Intoxication (smoking, alcohol) x
Body Structure and Functions
Pain
VAS diary pain x x x x x x
Mc Gill pain questionnaire x x x x x x
Sensory symptoms
Sensory testing [22] x x x x x x
Vasomotor
Thermometry [23] x x x x x x
Sudomotor/edema
Indirect volumetry [24] x x x x x x
Motor/trophic
Range of motion [25] x x x x x x
Dystonia (Fahn Marsden Scale) [26]+ x x x x x x
TREND Symptoms Inventory [27] x x x x x x
Participation
Radboud Skills Questionnaire [28]* ° x x x x x x
Walking Ability Questionnaire [29]"° x x x x x x
Rising & Sitting Ability Questionnaire [30]"° x x x x x x
Participation
Social Involvement Questionnaire [31] x x x x
Global Outcomes
SF-36 [32] x x x x
EQ-5D [33] x x x x
Environmental factors
Living situation, education, employment x x x x x x
Personal Factors
Tampa Scale of Kinesiophobia [34] x x x x
Hospital Anxiety & Depression scale [35] x x x x
Co-Morbidity [36] x x x x
+The Fahn Marsden Score will only be used in patients with clinical signs of dystonia.
*Only in patients with CRPS 1 in the upper extremity.
"Only in patients with CRPS 1 in the lower extremity.
°These questionnaires will be validated in German as a side project.Page 5 of 7
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study will guide investigators to set the research agenda in
this rapidly evolving field.
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